JAMA:呋喹替尼三线治疗转移性结肠癌效果显著

2018-06-27 zhangfan MedSci原创

研究认为,对于接受过2种化疗方案的转移性结肠癌患者,呋喹替尼治疗可显著延长患者生存期

转移性结直肠癌(CRC)患者的治疗手段十分有限,近日研究人员评估了血管内皮生长因子受体(VEGFR)抑制剂呋喹替尼三线治疗转移性CRC的疗效。

FRESCO为III期临床研究,在中国28个医疗中心开展,416名18-57岁先前接受过2种化疗(无VEGFR抑制疗法)后进展的CRC患者参与研究,随机接受5mg呋喹替尼(n?=?278)或安慰剂,每天1次持续28天,中间停药7天后,再接受28天治疗,直至疾病进展、不可接受毒性或退出。研究的主要终点为总生存期、次要终点包括无进展生存期、客观缓解及疾病控制率。

患者平均年龄54.6岁,女性占38.7%,97.1%的患者完成研究。呋喹替尼组患者平均总生存期(9.3 vs 6.6个月,死亡风险比值比为0.65)和无进展生存期(3.7 vs 1.8个月,进展或死亡比值比0.26)显著延长。呋喹替尼组61.2%的患者出现3-4级不良事件,而对照组为19.7%;呋喹替尼组严重不良事件率为15.5%,对照组为5.8%;14.4%的呋喹替尼组患者以及5.1%的对照组患者因治疗导致的不良事件入院。

研究认为,对于接受过2种化疗方案的转移性结肠癌患者,呋喹替尼治疗可显著延长患者生存期。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1386400, encodeId=45871386400a5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556085, encodeId=8c4315560859e, content=<a href='/topic/show?id=363119e4220' target=_blank style='color:#2F92EE;'>#三线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19742, encryptionId=363119e4220, topicName=三线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=438d14693621, createdName=smlt2013, createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327472, encodeId=4f1932e472cd, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Jun 27 17:04:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327395, encodeId=da4d32e39586, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Jun 27 09:25:09 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1386400, encodeId=45871386400a5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556085, encodeId=8c4315560859e, content=<a href='/topic/show?id=363119e4220' target=_blank style='color:#2F92EE;'>#三线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19742, encryptionId=363119e4220, topicName=三线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=438d14693621, createdName=smlt2013, createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327472, encodeId=4f1932e472cd, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Jun 27 17:04:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327395, encodeId=da4d32e39586, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Jun 27 09:25:09 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1386400, encodeId=45871386400a5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556085, encodeId=8c4315560859e, content=<a href='/topic/show?id=363119e4220' target=_blank style='color:#2F92EE;'>#三线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19742, encryptionId=363119e4220, topicName=三线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=438d14693621, createdName=smlt2013, createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327472, encodeId=4f1932e472cd, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Jun 27 17:04:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327395, encodeId=da4d32e39586, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Jun 27 09:25:09 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-06-27 cscdliu

    谢谢.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1386400, encodeId=45871386400a5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556085, encodeId=8c4315560859e, content=<a href='/topic/show?id=363119e4220' target=_blank style='color:#2F92EE;'>#三线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19742, encryptionId=363119e4220, topicName=三线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=438d14693621, createdName=smlt2013, createdTime=Thu Jun 28 23:36:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327472, encodeId=4f1932e472cd, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Jun 27 17:04:04 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327395, encodeId=da4d32e39586, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Jun 27 09:25:09 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-06-27 happsf

    学习

    0

相关资讯

GUT:口服抗凝血药或非甾体抗炎药不会影响结肠癌粪便免疫化学检测的准确性

研究发现,口服抗凝血药或非甾体抗炎药不会影响结肠癌粪便免疫化学检测的准确性,筛查前无需停药

Gastroenterology :直接反映腺瘤检测和切除的结肠镜筛查新指标

研究人员考察了2种全新的直肠癌乙状结肠镜筛查指标,新指标可以直接反映腺瘤的检测和切除,较筛查频率相比能更有效的指导胃肠外科的临床实践过程

Gastroenterology :AI图像系统可大大提高结肠镜腺瘤检出率

研究发现,图像分析AI技术可以快速定位息肉,对结肠息肉具有极高的检出率及准确性, 可大大提高结肠腺瘤检出率

Eur J Cancer:2期结肠癌,口服替加氟-尿嘧啶1年辅助化疗vs单独手术

2018年6月,发表于《Eur J Cancer》上的一项研究表明,2期结肠癌患者口服替加氟-尿嘧啶(UFT)1年辅助治疗并不优于单独手术治疗。

JAMA Surg:结肠癌患者不同全直肠系膜切除术方案与预后

研究证实不同的结肠癌手术方案对患者长期预后及临床效果的影响显著

Lancet:新辅助化疗后实现完全缓解的结肠癌患者可推迟手术

研究发现,新辅助化疗后实现完全缓解患者不接受手术治疗的5年生存率可达85%,晚期病变罕见,但患者2年内局部复发风险较高,且复发位点均位于肠壁处,这表明延期手术患者接受规律的内镜监测是十分重要的